Long‐term outcome of primary non‐responders to tenofovir therapy in <scp>HIV</scp>/<scp>HBV</scp>‐co‐infected patients: impact of <scp>HBV</scp> genotype G

Abstract

In these HBV/HIV-co-infected patients, first-line HBV therapy with tenofovir and emtricitabine or lamivudine was associated with EVR. However, DR to tenofovir was observed in 15% of patients who added tenofovir to lamivudine therapy, of whom four of seven (57%) had genotype G-HBV infection. No resistance was evidenced after 46 months of therapy even in patients with DR to tenofovir. At last, a good renal safety profile of TDF was observed after a median follow-up of 4 years of therapy.